Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone
PROpel Phase III trial results show clinically meaningful benefit in patients irrespective of homologous recombination repair gene mutations
Reno, Nevada (UroToday.com) — Positive results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus current standard-of-care abiraterone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.